Linoleic acid dietary intervention to decelerate biological aging via mitochondrial targeting

Overview

This solution centers on a dietary intervention that uses linoleic acid (LA)-rich safflower oil to target cardiolipin, a key phospholipid in mitochondrial membranes, with the goal of decelerating biological aging. The approach leverages a simple, low-dose supplementation strategy (10 g of oil daily) to improve mitochondrial fatty acid oxidation and influence aging-related biomarkers such as telomere length. The intervention has potential applications in healthy aging populations and in patients with conditions linked to mitochondrial dysfunction, including mild heart failure (HFpEF).

Technical specifications

Intervention design:

• Test product: linoleic acid-rich safflower oil (75% LA) delivered in gel capsules
• Comparator: oleic acid-rich safflower oil delivered in identical gel capsules
• Dosage: 10 g per day of dietary oil

Proposed validation study:

• 16-week double-blinded randomized controlled trial (RCT)
• Target population: adults with mild HFpEF heart failure (stage 1–2), with or without impaired kidney function
• Primary outcome: leukocyte telomere length comparison between groups
• Secondary outcomes: leukocyte cardiolipin composition, leukocyte mitochondrial function, cardiac magnetic resonance (CMR) imaging for heart failure, and body composition measured by DEXA
• Analytical factors: dietary LA, omega-3, protein, and saturated fat intake, plus sex, BMI, heart failure stage, and age

Pre-clinical and clinical evidence to date:

• Mice fed LA-fortified diets showed higher mitochondrial capacity and LA-rich cardiolipin and phospholipids in liver, muscle, and brown adipose tissue
• A clinical trial in healthy adults demonstrated increased LA-rich cardiolipin in peripheral blood mononuclear cells (PBMCs) after supplementation with 10 g LA-rich oils

Technology readiness level

The intervention is supported by pre-clinical mouse studies and an initial human clinical trial showing measurable changes in cardiolipin composition. The team is preparing a 16-week double-blinded RCT to validate effects on telomere length and mitochondrial function in older adults with mild heart failure. The study is estimated to require approximately 2.5 years to complete, with funding needed for key personnel, CMR imaging, leukocyte biochemistry, and participant costs. The technology is at an early-to-mid stage of clinical validation, with a clear path toward evidence generation in a defined patient population.